# Kigelia (Kigelia africana)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/kigelia
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** African
**Also Known As:** Kigelia africana, Sausage Tree, African Sausage Tree, Cucumber Tree, Worsboom, Mufuma, Mukwa, Botswanan Sausage Tree

## Overview

Kigelia africana is an African tree whose fruit extract contains bioactive compounds that demonstrate selective anti-cancer properties in laboratory studies. The extract works by suppressing EMT markers like Snail and survivin proteins in colorectal cancer cells while showing cytotoxicity against breast cancer cell lines.

## Health Benefits

• May inhibit colorectal cancer cell growth - fruit extract showed 77.3% reduction in EMT marker Snail and 52.2% suppression of survivin in HT-29 cells (preliminary in vitro evidence) • Potential selective anti-breast cancer effects - demonstrated cytotoxicity in MDA-MB-231 and MCF-7 cell lines while sparing non-cancer kidney cells (preliminary in vitro evidence) • Possible neuroblastoma suppression - dose-dependent inhibition of stage 4 neuroblastoma cell proliferation observed (preliminary in vitro evidence) • Traditional wound healing support - methanolic extract at 2 μg/ml promoted healing in HaCaT/BJ cells (preliminary in vitro evidence) • Historical use for benign prostatic hyperplasia - lipidosterolic extract tested in animal models, though human evidence lacking (traditional use only)

## Mechanism of Action

Kigelia fruit extract suppresses epithelial-mesenchymal transition (EMT) markers, specifically reducing Snail expression by 77.3% and survivin protein by 52.2% in colorectal cancer cells. The bioactive compounds appear to selectively target cancer cell survival pathways while sparing normal cells. The extract demonstrates cytotoxic effects against MDA-MB-231 and MCF-7 breast cancer cell lines through mechanisms that remain under investigation.

## Clinical Summary

Current evidence for Kigelia is limited to preliminary in vitro studies using cancer cell lines. Laboratory research showed 77.3% reduction in EMT marker Snail and 52.2% suppression of survivin in HT-29 colorectal cancer cells. Additional studies demonstrated selective cytotoxicity against MDA-MB-231 and MCF-7 breast cancer cell lines. No human clinical trials have been conducted to validate these preliminary findings or establish safety profiles.

## Nutritional Profile

{"macronutrients": {"carbohydrates": "Approximately 15-20 g per 100 g of fruit", "protein": "Approximately 1-2 g per 100 g of fruit", "fiber": "Approximately 3-5 g per 100 g of fruit"}, "micronutrients": {"vitamin_C": "Approximately 30-40 mg per 100 g of fruit", "calcium": "Approximately 50-70 mg per 100 g of fruit", "potassium": "Approximately 200-250 mg per 100 g of fruit"}, "bioactive_compounds": {"iridoids": "Present in significant amounts, exact concentration varies", "flavonoids": "Present, including luteolin and quercetin derivatives", "naphthoquinones": "Lawsone and related compounds present"}, "bioavailability_notes": "Nutrient absorption may be influenced by the presence of anti-nutritional factors such as tannins and oxalates, which can bind minerals and reduce their bioavailability."}

## Dosage & Preparation

No clinically studied dosages in humans are available. In vitro studies used various concentrations achieving cytotoxicity in cancer cell lines, with methanolic extract at 2 μg/ml for wound healing applications. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Safety data for Kigelia supplementation is extremely limited due to lack of human studies. Traditional use suggests general tolerability, but no formal toxicity studies have established safe dosage ranges. Potential interactions with chemotherapy drugs or hormone-sensitive medications are unknown and require medical supervision. Pregnancy and breastfeeding safety has not been established, making use inadvisable during these periods.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified; all evidence is limited to preclinical in vitro studies. Key studies include evaluation of fruit extract on HT-29 colorectal carcinoma cells showing modulation of 42 oncology proteins (PMID: 41515404), selective cytotoxicity on breast cancer cell lines (PMID: 38837975), and neuroblastoma proliferation inhibition (PMID: 36029541).

## Historical & Cultural Context

Kigelia africana has been used in African traditional medicine for centuries to treat wounds, rheumatism, psoriasis, diarrhea, stomach ailments, and male reproductive disorders. Fruits, leaves, and stems are applied topically or ingested, with emerging recognition for anticancer potential building on historical folk remedies.

## Synergistic Combinations

Cisplatin (laboratory synergy noted), African potato, Pygeum, Saw palmetto, Beta-sitosterol

## Frequently Asked Questions

### What compounds in kigelia cause anti-cancer effects?

The specific bioactive compounds responsible for kigelia's anti-cancer effects have not been fully identified in current research. Studies focus on whole fruit extract effects rather than isolated compounds, showing suppression of Snail and survivin proteins in cancer cells.

### How much kigelia extract was used in cancer studies?

Published studies do not specify exact dosages of kigelia fruit extract used in laboratory experiments. The research focuses on percentage effects on cancer cell markers rather than dose-response relationships, limiting practical application guidance.

### Can kigelia prevent colorectal cancer in humans?

No human studies exist to support kigelia's use for colorectal cancer prevention. Current evidence comes only from laboratory studies on isolated cancer cell lines, which cannot predict real-world effectiveness or safety in humans.

### Is kigelia safe to take with cancer medications?

Safety of combining kigelia with cancer medications is unknown due to lack of interaction studies. The extract's effects on cancer cell pathways could potentially interfere with conventional treatments, requiring oncologist consultation before use.

### What part of the kigelia plant is used medicinally?

Kigelia fruit extract is the primary medicinal preparation studied for anti-cancer properties. Traditional African medicine also uses bark and leaves, but scientific research focuses specifically on the large sausage-shaped fruits of Kigelia africana.

### What is the current research quality on kigelia's anti-cancer effects in humans?

Current evidence for kigelia's anti-cancer effects comes primarily from in vitro (lab cell) studies showing promising results in colorectal and breast cancer cell lines, but human clinical trials are lacking. The 77.3% reduction in EMT markers and 52.2% survivin suppression observed in HT-29 colorectal cancer cells represent preliminary findings that have not yet been validated in human studies. More robust clinical research is needed before kigelia can be recommended as a cancer prevention or treatment agent. These early results are encouraging but should not be interpreted as proof of efficacy in living humans.

### Who should avoid taking kigelia supplements?

Pregnant and breastfeeding women should avoid kigelia due to insufficient safety data in these populations, and traditional use suggests potential uterotonic effects. Individuals with existing cancer or those undergoing cancer treatment should consult their healthcare provider before using kigelia, as its interactions with conventional oncology treatments are not well-established. People with kidney or liver disease should exercise caution, as kigelia's metabolism and clearance pathways have not been thoroughly characterized in compromised populations.

### How does kigelia's anti-cancer selectivity compare to other herbal extracts?

Kigelia demonstrates notable selectivity in preliminary studies by showing cytotoxicity against cancer cell lines (MDA-MB-231, MCF-7) while sparing non-cancer kidney cells, suggesting a degree of cancer-specific targeting that is valuable in early screening. This selective toxicity profile is similar to certain other traditional plant extracts being researched, though direct comparative studies between kigelia and other herbal candidates are limited. The specificity observed in vitro makes kigelia a candidate worthy of further investigation, but this advantage has not been confirmed in human studies or compared systematically to established botanical anti-cancer agents.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*